Nuformix plc

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. Its lead programs include NXP001, which is in Phase 1-ready stage for oncology supportive care; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. The company is also developing NXP004, which is in the…More research Phase for treating oncology. It also has an option agreement with Oxilio Ltd. for developing and exploiting NXP001 for the treatment of cancer. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.